Boston Scientific’s next stent
This article was originally published in The Gray Sheet
FDA approves investigational device exemption for ATLAS clinical trial of the Taxus Liberté next-generation paclitaxel-eluting stent system. The prospective, single-arm study will enroll 822 patients at 60 sites in the U.S., Canada, Australia, New Zealand, Singapore, Hong Kong and Taiwan. A slow-release formulation of Liberté will be evaluated to show non-inferiority compared with a historical control (combined TAXUS IV and V studies), with an endpoint of nine-month target vessel revascularization...
You may also be interested in...
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.